source
- STAT+: Neurocrine Biosciences and the delicate balance of benefit and riskWhen it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.STAT · 10m ago↗ source
- STAT+: Newsom promotes affordable insulin, but California’s generic label is off to a slow startGov. Gavin Newsom is focused on making health care affordable, but his CalRx insulin has been slow to reach patients.STAT · 2h ago↗ source
- STAT+: As young people increasingly get cancer, new fertility options are changing their futuresNew technologies, cancer doctors, and reproductive specialists are working to give more patients a chance to have children post-treatment.STAT · 2h ago